Public Sector Pension Investment Board Sells 4,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Public Sector Pension Investment Board lowered its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.3% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 116,949 shares of the specialty pharmaceutical company’s stock after selling 4,000 shares during the period. Public Sector Pension Investment Board owned 0.21% of Supernus Pharmaceuticals worth $3,646,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of SUPN. SG Americas Securities LLC grew its holdings in Supernus Pharmaceuticals by 377.3% during the second quarter. SG Americas Securities LLC now owns 18,064 shares of the specialty pharmaceutical company’s stock worth $483,000 after purchasing an additional 14,279 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in Supernus Pharmaceuticals by 6.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 42,449 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after acquiring an additional 2,605 shares during the last quarter. Louisiana State Employees Retirement System lifted its position in Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after acquiring an additional 600 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Supernus Pharmaceuticals by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company’s stock worth $11,379,000 after acquiring an additional 2,427 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Supernus Pharmaceuticals by 20.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,083 shares of the specialty pharmaceutical company’s stock worth $350,000 after acquiring an additional 2,225 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.

Supernus Pharmaceuticals Trading Up 2.0 %

NASDAQ SUPN opened at $37.31 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The company has a 50 day moving average of $34.20 and a 200-day moving average of $31.35. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 34.87 and a beta of 0.86.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same period in the previous year, the business earned ($0.29) earnings per share. The firm’s quarterly revenue was up 14.2% on a year-over-year basis. On average, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Activity at Supernus Pharmaceuticals

In related news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock valued at $5,660,180 over the last three months. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.